PRKACA and fibrolamellar hepatocellular carcinoma: (NCT05937295, FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition, Tuebingen, Baden-Würtemberg, Germany; NCT04248569, DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma, Baltimore, MD, USA).